Trastuzumab approved by NICE for gastric cancer
Trastuzumab, in combination with cisplatin and capecitabine or 5-fluorouracil, has been approved by the National Institute for Health and Clinical Excellence for the treatment of HER2-positive metastatic gastric cancer.
NICE has also updated its guidance on the use of imatinib for metastatic or unresectable gastrointestinal stromal tumours (TA86); high doses of imatinib (600–800mg/day) are not recommended for patients whose disease has progressed while taking 400mg/day.
Citation: Clinical Pharmacist URI: 11048915
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com